Phase I Safety and Immunogenicity Study of VAX102 [Flagellin.HuM2e] Influenza Vaccine in Healthy Adults

Inclusion Criteria: * Healthy adults aged 18-49 years inclusive who provide written informed consent to participate. * Comprehension of the study requirements, expressed availability for the required study period, and ability to attend scheduled visits. Exclusion Criteria: * Presence of significant acute or chronic, uncontrolled medical or psychiatric illness * Documented influenza infection in the 6 months prior to study entry. * Presently receiving or history of receiving any medications or treatments that affects the immune system * Acute disease within 72 hours prior to vaccinations Investigational product (test article) administrations will occur on Days 0 and 28 (± 3). * In-clinic safety evaluations will be performed at screening, before each test article dose, and at Days 1, 7 (± 2), 14 (± 2), 29, 35 (± 2), 42 (± 2), 60 (± 2), 120 (± 7), and 180 (± 7). * Completion of a Memory Aid for seven days following each vaccine dose will be requested of subjects for use in accurate recall of local and systemic reactions.